Skip to main content

Table 1 Clinicopathologic features of patients with ovarian seromucinous borderline tumors with or without endometriosis

From: PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis

Characteristics All
(N = 69)
Without endometriosis
(N = 29)
With endometriosis
(N = 40)
P value
Age (yrs) 35.0 (30.0–43.0) 33.0 (30.0–44.5) 35.0 (30.2–41.5) 0.889
BMI (kg/m2) 20.7 (19.1–22.3) 20.9 (19.4–23.2) 20.5 (18.8–22.2) 0.508
Nulliparous 45 (65.2) 19 (65.5) 26 (65.0) 0.964
Menopause 9 (13.0) 4 (13.8) 5 (12.5) 1.000
Borderline op history 7 (10.1) 3 (10.3) 4 (10.0) 1.000
Endometriosis op history 3 (4.3) 0 (0) 3 (7.5) 0.258
ART history 4 (5.8) 2 (6.9) 2(5.0) 1.000
Tumor and treatment
Serum CA125 (U/ml) 37.9 (17.6–62.9) 30.0 (17.1–56.5) 39.6 (17.3–63.6) 0.586
 Normal 28 (44.4) 14 (53.8) 14 (37.8) 0.208
 Elevated 35 (55.6) (n = 63) 12 (46.2) (n = 26) 23 (62.2) (n = 37)  
Tumor size (cm) 6.3 (4.5–8.3) 6.0 (4.1–9.5) 6.3 (4.6–8.2) 0.894
Surgical method
 Laparoscopy 65 (94.2) 26 (89.7) 39 (97.5) 0.302
 Laparotomy 4 (5.8) 3 (10.3) 1 (2.5)  
Tumorectomy method     0.620
 Cystectomy 19 (27.5) 9 (31.0) 10 (25.0)  
 USO 38 (55.1) 14 (48.3) 24 (60.0)  
 TH with BSO 12 (17.4) 6 (20.7) 6 (15.0)  
Staging operation     0.863
 Not done 23 (33.3) 10 (34.5) 13 (32.5)  
 Comprehensive 46 (66.7) 19 (65.5) 27 (67.5)  
Stage     0.167
 1A 29 (42.0) 11 (37.9) 18 (45.0)  
 1B 3 (4.3) 3 (10.3) 0 (0)  
 1C 36 (52.2) 15 (51.7) 21 (52.5)  
 2B 1 (1.4) 0 (0) 1 (2.5)  
Bilaterality of borderline tumor 5 (7.2) 3 (10.3) 2 (5.0) 0.643
Capsule involvement 5 (7.2) 4 (13.8) 1 (2.5) 0.154
Intraepithelial carcinoma 4 (5.8) 1 (3.4) 3 (7.5) 0.634
Microinvasion 9 (13.0) 4 (13.8) 5 (12.5) 1.000
Non- invasive implant 1 (1.4) 0 (0) 1 (2.5) 1.000
Peritoneal cytology 4 (10.8) (n = 37) 2 (14.3) (n = 14) 2 (8.7) (n = 23) 0.625
Pelvic adhesion 19 (27.5) 6 (20.7) 13 (32.5) 0.278
Outcomes
Pregnancy outcome 9 (15.8) (n = 57) 2 (8.7) (n = 23) 7 (20.6) (n = 34) 0.288
Recurrence of borderline tumor 3 (4.3) 0 (0) 3 (7.5) 0.258
PFS, month 28.0 (12.5–60.0) 29.0 (11.5–60.0) 28.0 (12.5–61.0) 0.860
OS, month 29.0 (12.5–60.5) 29.0 (11.5–60.0) 28.0 (12.5–66.2) 0.831
  1. Data were shown as median and interquartile ranges or numbers (percentages)
  2. EM endometriosis, BMI body mass index, ART assisted reproductive technology, USO unilateral salpingo-oophrectomy, TH total hysterectomy, BSO bilateral salpingo-oophorectomy, LND lymph node dissection, PFS progression-free survival, OS overall survival